Prostatype Genomics FCF/Debt
The Free Cash Flow to Debt Ratio of Prostatype Genomics (PROGEN.ST) as of Oct 12, 2026 is -453.94 %. In the previous year, Free Cash Flow to Debt Ratio was -78,465.67 % — a change of -99.42% (higher).
Get this data via API
Financial Data API
FCF/Debt
-453.94 %
YoY
-99.42%
Last updated:
The Prostatype Genomics FCF/Debt history
3 Years
10 Years
25 Years
Max
| YEAR | FCF/Debt | YoY |
|---|---|---|
| -453.94 % | -99.42% | |
| -78,465.67 % | +24,182.73% | |
| -323.13 % | -89.88% | |
| -3,194.12 % | +117.78% | |
| -1,466.67 % | +45.96% | |
| -1,004.87 % | +434.10% | |
| -188.14 % | +73.72% | |
| -108.30 % | -76.58% | |
| -462.42 % | — |
Prostatype Genomics Stock analysis
Frequently Asked Questions about Prostatype Genomics stock
Free Cash Flow to Debt Ratio of Prostatype Genomics is -453.94 % in 2025.
Free Cash Flow to Debt Ratio of Prostatype Genomics changed from -78,465.67 % to -453.94 %, representing a -99.42% change. The value is higher than the previous year.
On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Prostatype Genomics since 2006 – with annual values, charts, and detailed analysis.
FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.
A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Prostatype Genomics with sector peers and the industry average to assess whether it is attractive.
Leverage — Prostatype Genomics
All Key Metrics — Prostatype Genomics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth